XBiotech Inc
4XB
Company Profile
Business description
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact
5217 Winnebago Lane
AustinTX78744
USAT: +1 512 386-2900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
stocks
Overvalued ASX share hurt by normalising conditions
Investors overly optimisitc about future prospects.
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,109.40 | 32.50 | 0.36% |
| CAC 40 | 8,072.67 | 122.49 | 1.54% |
| DAX 40 | 23,991.90 | 421.94 | 1.79% |
| Dow JONES (US) | 47,142.10 | 155.00 | 0.33% |
| FTSE 100 | 9,797.85 | 115.28 | 1.19% |
| HKSE | 26,649.06 | 163.16 | 0.62% |
| NASDAQ | 23,462.15 | 457.61 | 1.99% |
| Nikkei 225 | 50,911.76 | 28.08 | 0.06% |
| NZX 50 Index | 13,617.48 | 40.67 | 0.30% |
| S&P 500 | 6,807.88 | 79.08 | 1.18% |
| S&P/ASX 200 | 8,835.90 | 25.40 | 0.29% |
| SSE Composite Index | 4,018.60 | 21.04 | 0.53% |